COLORADO SPRINGS, Colo.,
Aug. 26, 2014 /PRNewswire/ --
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing
in cannabis formulation-based drug development and related
consulting, is pleased to provide a guidance report on its current
pre-clinical drug development programs underway, beginning with the
scientific cannabis cultivation programs in Europe and North
America, testing multiple cannabis strains for multiple
critical ailments.
Mr. Mario S. Lap, Director and
President of European Operations, stated, " The Company's efforts
in Spain compliment Cannabis
Science's plans in Canada and the
Company's current, pre-clinical collaboration with the Institute
for Research, Hospitalization and Health Care on Ageing (INRCA) in
Italy, where the Company is
testing toxicity and efficacy of cannabinoid formulations for
neurobehavioral diseases including sleep disorders."
The facilities are located in the Alicante region of
Spain; the Company has
successfully initiated an agricultural program spanning combined 15
hectares parceled according to seed strains and growth cycles and
protocols. Focused on GMP production requirements and research
framework to conduct scientific testing of the active constituents
contained in the cannabis plant. The company will set these
protocols to multiply optimal results into drug formulation
regiments for pre-clinical studies.
The current progress is based on multiple harvests processed
thus far and proprietary harvest process and successful transitions
into extracts for multiple targeted drug development. The Company
has now received data on three harvests for hemp and expecting its
cannabis results shortly. This data is critical in the
initial stages of our drug development programs as it can be
replicated on an international basis for multiple jurisdictional
drug development programs.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.